Concepedia

Author

Hamid Emamekhoo

University of Wisconsin–MadisonORCID

Also Known As

H. Emamekhoo, HAMID EMAMEKHOO, Hamid Emamekhoo, Hikmat Al-Ahmadie, Jenny J Kim, Paul Celano, Pedro Barata

212

Publications

2.5K

Citations

25

H-Index

60

Concepts

All Affiliations

University of Wisconsin–MadisonUniversity of Wisconsin Carbone Cancer CenterDana-Farber Cancer InstituteCleveland ClinicUniversity of Michigan
HE

About

Hamid Emamekhoo is an author at University of Wisconsin–Madison specializing in medicine, oncology, and urology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

17

860

2

Health Sciences

5

5

148

3

Diagnostic Sciences

2

2

30

4

Public Health

1

1

19

5

Endocrinology

1

1

30

Hamid Emamekhoo

×

41

Publications

1.8K

Citations

23

H-Index

YearCitations

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy D. Gilligan, Daniel W. Lin, Rahul Aggarwal,

Journal of the National Comprehensive Cancer Network

2019

440

Comparative transfection of DNA into primary and transformed mammalian cells from different lineages

Rosalie Maurisse, David de Semir, Hamid Emamekhoo,

BMC Biotechnology

2010

181

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung‐Han Lee, Robert J. Motzer, Hamid Emamekhoo,

Clinical Cancer Research

2022

97

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Vadim S. Koshkin, Nicholas Henderson, Marihella James,

Cancer

2021

80

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master,

The Lancet Oncology

2024

64

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Kyle T. Helzer, Marina N. Sharifi, Jamie M. Sperger,

Annals of Oncology

2023

61

Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer

Jamie M. Sperger, Hamid Emamekhoo, Rana R. McKay,

Journal of Clinical Oncology

2021

59

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer

Mohammad Alyamani, Hamid Emamekhoo, Sunho Park,

Journal of Clinical Investigation

2018

52

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

Dana E. Rathkopf, Manish R. Patel, Atish D. Choudhury,

Annals of Oncology

2024

50

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Douglas G. McNeel, Jens C. Eickhoff, Ellen Wargowski,

Journal for ImmunoTherapy of Cancer

2022

47

Page 1